期刊文献+

弥漫大B细胞淋巴瘤外周血IL-18、IL-1β的表达水平及其临床意义

Expression levels and clinical significance of IL-18 and IL-1βin peripheral blood of diffuse large B-cell lymphoma
暂未订购
导出
摘要 目的探讨NOD样受体热蛋白结构域相关蛋白3(NLRP3)炎症小体相关炎症因子白细胞介素-18(IL-18)和白细胞介素-1β(IL-1β)在弥漫大B细胞淋巴瘤(DLBCL)中的表达情况,并分析其与患者预后的关系。方法将2020年7月至2021年7月在广西医科大学附属肿瘤医院接受治疗的50例初治DLBCL患者设为DLBCL组,同期选取50名健康体检者作为健康对照组,检测并比较IL-18、IL-1β水平。绘制受试者工作特征(ROC)曲线确定IL-18、IL-1β预测患者死亡或存活的最佳截断值,将患者分为高表达组和低表达组。对DLBCL患者随访至2024年6月30日,记录其3年总生存期(OS),并分析IL-18和IL-1β水平与预后的关系。结果DLBCL组的IL-18、IL-1β水平均显著高于健康对照组,差异具有统计学意义(P<0.05)。ROC曲线结果显示,IL-18的最佳截断值为19.15 pg/mL,IL-1β的最佳截断值为4.95 pg/mL。IL-18、IL-1β高水平组的临床分期Ⅲ/Ⅳ期占比高于低水平组(P<0.05)。Log-rank检验显示,IL-18、IL-1β高水平组DLBCL患者的3年OS显著低于低水平组(P<0.001)。结论NLRP3炎症小体相关炎症因子IL-18和IL-1β在DLBCL患者中表达水平较高,与患者的不良预后密切相关。 Objective To investigate the expression of interleukin-18(IL-18)and interleukin-1β(IL-1β)of NOD-like receptor pyrin domain containing protein 3(NLRP3)inflammasome-related inflammatory factors in diffuse large B-cell lymphoma(DLBCL),and to analyze their relationship with the prognosis of patients.Methods A total of 50 patients with newly diagnosed DLBCL who were treated in the Affiliated Cancer Hospital of Guangxi Medical University from July 2020 to July 2021 were set as DLBCL group,and 50 healthy subjects were selected as healthy control group during the same period.IL-18 and IL-1β levels were detected and compared.The optimal cut-off values of IL-18 and IL-1β levels for predicting the death or survival of patients were determined by drawing the receiver operating characteristic(ROC)curve,and the patients were divided into high expression group and low expression group.The patients with DLBCL were followed up until June 30,2024,their 3-years overall survival(OS)was recorded,and the relationship between IL-18 and IL-1βlevels and prognosis was analyzed.Results The levels of IL-18 and IL-1βin the DLBCL group were significantly higher than those in the healthy control group,and the differences were statistically significant(P<0.05).The results of ROC curve showed that the optimal cut-off value of IL-18 was 19.15 pg/mL,and the optimal cut-off value of IL-1βwas 4.95 pg/mL.The proportion of clinical stage Ⅲ/Ⅳ in the high level group of IL-18 and IL-1β was higher than that in the low level group(P<0.05).Log-rank test showed that the 3-years OS of DLBCL patients in the high level group of IL-18 and IL-1β was significantly lower than that in the low level group(P<0.001).Conclusion The expression levels of IL-18 and IL-1β of NLRP3 inflammasome-related inflammatory factors are higher in DLBCL patients,which are closely related to the poor prognosis of patients.
作者 王明月 段莹 黄鑫 岑洪 钟大妮 WANG Mingyue;DUAN Ying;HUANG Xin;CEN Hong;ZHONG Dani(Affiliated Cancer Hospital of Guangxi Medical University,Nanning 530000,China)
出处 《临床医学研究与实践》 2025年第7期62-65,共4页 Clinical Research and Practice
基金 广西自然科学基金项目(No.2024GXNSFBA010319) 广西壮族自治区卫生健康委员会自筹经费科研课题(No.Z20190669)。
关键词 白细胞介素-18 白细胞介素-1Β 弥漫大B细胞淋巴瘤 interleukin-18 interleukin-1β diffuse large B cell lymphoma
  • 相关文献

参考文献8

二级参考文献32

  • 1Korl AD, le Gessie S, Snijder S, et al. Primary extranodal non- Hodgkin' s lymphoma (NHL): the impact of alternative defini- tions tested in the Comprehensive Cancer Centre West popula- tion-based NHL registry. Ann Oncol, 2003, 14:131-139.
  • 2Li XQ, Li GD, Gao ZF, et al. The relative frequencies of lympho- ma subtypes in China: a nationwide study of 10002 cases by the Chinese Lymphoma Study Group. Ann Oncol, 2011, 22 Suppl 4: ivl41.
  • 3Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan- dard regimen (CHOP) with three intensive chemotherapy regi- mens for advanced non-Hodgkin' s lymphoma. N Engl J Med, 1993, 328:1002-1006.
  • 4Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med, 2005, 352:1197-1205.
  • 5Coiffier B, Thieblemont C, Van Den Neste E,et ah Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemother- apy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de 1' Adulte. Blood, 2010, 116:2040-2045.
  • 6Seki R, Ohshima K, Nagafuji K, et al. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group. Int J Hematol, 2010, 9 I: 258-266.
  • 7Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol, 2005, 23:5027-5033.
  • 8Habermama TM, Weller EA, Morrison VA, et al. Rituximab- CHOP versus CHOP alone or with maintenance rituximab in old- er patients with diffuse large B-cell lymphoma. J Clin Oncol, 2006, 24:3121-3127.
  • 9Tilly H, Dreyling M. ESMO Guidelines Working Group. Diffuse large B-cell non-Hodgkin' s lymphoma: ESMO clinical recom- mendations for diagnosis, treatment and follow-up. Ann Oncol, 2008, Suppl 2:ii67-69.
  • 10NCCN Guidelines. Non-Hodgkin' s Lymphomas, version 2.2012.

共引文献302

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部